Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients

(MedPage Today) -- Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe disease, according to final...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news